Business
Medicure announces filing of ANDA in collaboration with Apicore
Medicure announces filing of ANDA in collaboration with Apicore Medicure announces...
About this update from Medicure Inc.
[{"type":"text","content":"\n\n\n\nMedicure announces filing of ANDA in collaboration with Apicore\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMedicure announces filing of ANDA in collaboration with Apicore\nCanada NewsWire\nWINNIPEG, Dec. 13, 2016\n\n\n\nWINNIPEG, Dec. 13, 2016 /CNW/ - Medicure Inc. (\"Medicure\" or the \"Company\") (TSXV:MPH, OTC:MCUJF), a leading Canadian specialty pharmaceutical company, is pleased to announce that an abbreviated New Drug Application (\"ANDA\") was filed with the U.S. Food and Drug Administration for a high-value cardiovascular generic drug developed as a collaboration between Medicure International, Inc. (a wholly owned subsidiary of Medicure Inc.)  and Apicore US LLC (together with its affiliates \"Apicore\"). The ANDA filing is the result of a project that was previously announced on January 6, 2016 and was focused on the development of an intravenous drug product for an acute cardiovascular indication.  Medicure and Apicore have entered into an exclusive product supply and development agreement under which Medicure holds all commercial rights.\n\nMedicure owns a majority interest in Apicore, as well as an option to acquire the remaining issued shares of Apicore until July 2017.\n\nAbout Apicore\n\nApicore is a private, New Jersey based developer and manufacturer of specialty Active Pharmaceutical Ingredients (\"APIs\") and pharmaceuticals, including over 15 Abbreviated New Drug Applications (\"ANDAs\"), one of which, is partnered with Medicure.  Apicore manufactures over 100 different API's, including over 35 for which Drug Master Files have been submitted to the FDA and 12 that are approved for commercial sale in the U.S. by customers of Apicore.  Apicore specializes in the manufacture of difficult to synthesize, high value and other niche API's for many U.S. and international generic and branded pharmaceutical companies.  Apicore has 2 FDA-approved facilities. In the U.S., the Somerset, New Jersey facility can produce a few grams up to 200 kg volumes and in India, the Vadodara, Gujarat facility c...